In 2019, Pembrolizumab was approved by the USA FDA to be used to treat relapsed, locally advanced or metastatic ESCC patients who had received first-line or later-line systemic treatment, with positive PD-L1 expression in tumor tissues (CPS≥10). Here, CD274 is linked to esophageal squamous cell carcinoma.